The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.
 
David S. Hong
Stock and Other Ownership Interests - OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; Atheneum; AUM Biosciences; Axiom Biotechnologies; Barclays; Baxter; Bayer; Boxer Capital; Bridgebio; CDR-Life; COG; Cor2Ed; EcoR1 Capital; Genentech; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Shadia Ibrahim Jalal
Consulting or Advisory Role - Adaptimmune
Research Funding - Astex Pharmaceuticals; AstraZeneca/MedImmune; Tesaro
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
Research Funding - Bristol-Myers Squibb; Zymeworks
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Mariela A. Blum Murphy
Honoraria - Jounce Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Andres Cervantes
Consulting or Advisory Role - Amgen (Inst); BeiGene (Inst); BMS (Inst); Merck Serono (Inst)
Research Funding - Abbvie (Inst); Activate Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Bioncotech (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); F. Hoffmann LaRoche (Inst); FibroGen (Inst); Genmab (Inst); Janssen Research & Development (Inst); MedImmune (Inst); Menarini (Inst); Novartis (Inst); Puma Biotechnology (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Transgene (Inst); WntResearch (Inst)
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Quan Lin
Employment - Adaptimmune; Novocure (I)
Stock and Other Ownership Interests - Adaptimmune; Novocure (I)
Patents, Royalties, Other Intellectual Property - Baylor College of Medicine (I)
 
Paul Noto
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Michael Shnaidman
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Daniel Campbell
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Marisa Rosenberg
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
Travel, Accommodations, Expenses - Adaptimmune
 
Francine Elizabeth Brophy
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Hassan Danesi
Employment - Adaptimmune
Leadership - Adaptimmune (Inst)
Stock and Other Ownership Interests - Adaptimmune (Inst)
Travel, Accommodations, Expenses - Adaptimmune (Inst)
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IQvia; Lilly/ImClone; Macrogenics; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical